强生公司宣布，欧洲药品管理局（EMA）人用药品委员会（CHMP）已推荐扩展其抗癌药物Darzalex（daratumumab）皮下注射（SC）剂型的适应症，此举将用于一线治疗新确诊的多发性骨髓瘤成年患者。推荐基于3期临床试验CEPHEUS的数据，该试验评估了Darzalex联合硼替佐米、来那度胺和地塞米松（D-VRd）的安全性和疗效。该数据将于2024年在国际骨髓瘤学会（IMS）年会和美国血液学会 ...

She volunteered at the Cancer Society and visited hospice patients, offering meditation and relaxation practices.

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has opined IQVIA to conduct the bioequivalence study or present safety data for ...

Morningstar brands and products Company Portfolio ...

has entered into a licence agreement with Shanghai Henlius Biotech Inc for the development and commercialisation of the Chinese player’s investigational daratumumab biosimilar candidate HLX15.

EU and CN sourced daratumumab. The company is now conducting comparative efficacy studies.